
Inoviq develops exosome technologies for cancer detection and treatment and commercialised the EXO-NET research tool and hTERT bladder test.
inoviq.comCrawled Nov 19, 2026
Biotechnology firm **INOVIQ** announces CEO **Dr Leearne Hinch** will resign from her executive role on **27 October 2026**. The company’s chairman will assume an interim leadership position during the transition. INOVIQ specializes in exosome-based diagnostics and therapeutics.
INOVIQ reports a **$7.5 million net loss** for FY2026, driven by the failure of its **EXO-OC™ ovarian cancer test** clinical study. The study halted due to **poor-quality samples** from commercial biobanks, impacting development progress. The company’s financial performance reflects challenges in advancing its diagnostic pipeline.
INOVIQ is progressing its exosome-based blood test for ovarian cancer toward a US market entry. The company plans to launch initially as a laboratory developed test (LDT) for high-risk women. CEO Dr. Leearne Hinch has outlined the early commercialization strategy for the test.
INOVIQ is advancing its exosome-based blood test, **EXO-OC**, for early detection of ovarian cancer in asymptomatic women aged 45 to 74. The company’s patented platform integrates research tools, diagnostics, and therapeutics, with EXO-OC targeting improved screening through liquid biopsy technology. INOVIQ’s work focuses on leveraging exosomes—tiny biological particles—to identify cancer biomarkers in blood samples.
INOVIQ raises **$9.5 million** through a placement to institutional and sophisticated investors and secures an additional **$2 million** via a share purchase plan (SPP). The funds will accelerate development of its **exosome-based ovarian cancer diagnostic test**, leveraging proprietary technology for cancer care diagnostics and therapeutics.
INOVIQ acquires an exclusive global licence for UniQuest’s exosomal biomarkers, enabling early ovarian cancer detection. The biomarkers target novel diagnostic approaches for improved patient outcomes. The agreement grants INOVIQ full rights to develop and commercialize the technology worldwide.
Innovate unveils clinical trial data demonstrating **77% sensitivity and 99.6% specificity** in ovarian cancer screening across all stages, meeting critical benchmarks for large-scale population testing. The findings were presented at the **American Society of Clinical Oncology (ASCO) meeting**, validating the technology’s potential for early detection. Innovate’s approach targets unmet needs in ovarian cancer, where late-stage diagnoses remain common.
The Australian Securities Exchange (ASX) questioned Inoviq about whether its cancer research announcement conveyed a fair and balanced impression, citing concerns over the early-stage nature of the study. The inquiry follows scrutiny of the company’s headline claims regarding its research findings. Inoviq operates in the biotech sector, focusing on cancer therapies.